Ramon Hendrickx

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O 43183, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists.

TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists.

Journal: Journal of medicinal chemistry

Published: July 11, 2026

Difference in Exposure and Tolerability when Comparing Intratracheal Instillation with Inhaled Delivery.

Difference in Exposure and Tolerability when Comparing Intratracheal Instillation with Inhaled Delivery.

Journal: Journal of aerosol medicine and pulmonary drug delivery

Published: September 03, 2025

A novel in vitro high-content imaging assay for the prediction of drug-induced lung toxicity.

A novel in vitro high-content imaging assay for the prediction of drug-induced lung toxicity.

Journal: Archives of toxicology

Published: February 29, 2024

Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization.

Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization.

Journal: Journal of medicinal chemistry

Published: September 22, 2023

Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata.

Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata.

Journal: Skin health and disease

Published: October 31, 2022

Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma.

Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma.

Journal: Drug design, development and therapy

Published: December 22, 2021

Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.

Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.

Journal: The Lancet. Rheumatology

Published: September 09, 2019

Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile.

Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile.

Journal: Journal of medicinal chemistry

Published: February 10, 2018

Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.

Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.

Journal: Journal of medicinal chemistry

Published: September 23, 2017

Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.

Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.

Journal: CPT: pharmacometrics & systems pharmacology

Published: August 01, 2017

Discovery of indazole ethers as novel, potent, non-steroidal glucocorticoid receptor modulators.

Discovery of indazole ethers as novel, potent, non-steroidal glucocorticoid receptor modulators.

Journal: Bioorganic & medicinal chemistry letters

Published: August 12, 2016

Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.

Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.

Journal: Journal of medicinal chemistry

Published: August 30, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026